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Introduction. The aim of this study was to determine the frequency of pseudoprogression in a cohort of glioblastoma (GBM)
patients following radiotherapy/temozolomide (RT/TMZ) by comparing Macdonald criterial to Response Assessment in Neuro-
Oncology (RANO) criteria. The impact on prognosis and survival analysis was also studied. Materials and Methods. All
patients receiving RT/TMZ for newly diagnosed GBM from January 2005 to December 2009 were retrospectively evaluated,
and demographic, clinical, radiographic, treatment, and survival data were reviewed. Updated RANO criteria were used for the
evaluation of the pre-RT and post-RT MRI and compared to classic Macdonald criteria. Survival data was evaluated using the
Kaplan-Meier and log-rank analysis. Results and Discussion. 70 patients were available for full radiological response assessment.
Early progression was confirmed in 42 patients (60%) according to Macdonald criteria and 15 patients (21%) according to RANO
criteria. Pseudoprogression was identified in 10 (23.8%) or 2 (13.3%) patients in Macdonald and RANO groups, respectively.
Cumulative survival of pseudoprogression group was higher than that of true progression group and not statistically different
from the non-progressive disease group. Conclusion. In this cohort, the frequency of pseudoprogression varied between 13% and
24%, being overdiagnosed by older Macdonald criteria, which emphasizes the importance of RANO criteria and new radiological
biomarkers for correct response evaluation.
1. Introduction
The current standard of care for newly diagnosed glioblas-
toma (GBM) remains surgical resection followed by radio-
therapy with concurrent temozolomide (RT/TMZ) and then
maintenance temozolomide for at least six months [1]. The
addition of chemotherapy introduced new questions regard-
ing biological response of the tumor and the surrounding
brain. Pseudoprogression is a phenomenon of subacute imag-
ing changes in human glioma subsequent to radiochemo-
therapy suggestive of progression, with or without associated
clinical sequelae, which resolve spontaneously without fur-
ther therapy [2]. It was first reported by Hoffman et al. [3]
in 1979 and fully described by de Wit et al. [4] in 2004.
The underlying pathophysiological mechanisms are not fully
understood [5]. Some authors suggest that it likely reflects
an inflammatory tissue reaction after a local treatment sec-
ondary to vascular and oligodendroglial injury, whereas
others associate it with an exaggerated response to effective
therapy [2, 6, 7].
The incidence of pseudoprogression, time of occurrence,
and its impact on prognosis remain poorly defined. Incidence
has been reported to vary between 12% and 64% in different
series, and this phenomenon commonly occurs in the first
3 months after radiochemotherapy, occasionally persisting
for up to six months after treatment [2, 5] Imaging changes
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suggestive of pseudoprogression consist of an increase in
gadolinium enhancement on T1-weighted images and peritu-
moral edema [5, 8]. Despite technical advances in perfusion
magnetic resonance imaging (MRI) and positron emission
tomography (PET), no imaging technique is yet validated for
detection of pseudoprogression and has not been incorpo-
rated into the latest response assessment criteria [9–11].
Genetic and molecular changes have also been associated
with pseudoprogression. Specifically p53 overexpression [12],
O(6)-methylguanine-DNA methyltransferase (MGMT) pro-
motermethylation status [13], Ki67 indices [14], and isocitrate
dehydrogenase 1 (IDH1) mutation have been reported as
potential biomarkers for detecting pseudoprogression [15].
The response of brain tumors is classically reported using
Macdonald criteria based on the two-dimensional measure-
ment of the enhancing area on CT or MRI, in conjunction
with clinical assessment and corticosteroid dose [6]. How-
ever, this response evaluation has important limitations since
posttreatment contrast enhancement in brain tumors is non-
specific and may not always be considered as a true surrogate
of tumor response [16]. Differentiation between pseudopro-
gression and real progression is critical for making decisions
on future therapy and for predicting the prognosis in clinical
practice [17].
The purpose of this study was to clarify the frequency of
pseudoprogression after radiochemotherapy in a cohort of
Portuguese patients with glioblastoma, by comparing RANO
with the classical Macdonald evaluation.
2. Materials and Methods
One hundred seventeen adult patients with newly diag-
nosed glioblastoma were treated between January 2005 and
December 2009 with radiochemotherapy according to the
Stupp protocol. Seventy patients were available for complete
radiological response assessment.
All patients were retrospectively evaluated, and demo-
graphic, clinical, radiographic, treatment, and survival data
were reviewed. The inclusion criteria were age ≥18 years with
histologically proved glioblastoma and the availability ofMRI
imaging less than 72 hours postoperatively and at each 3
months to define response. Response assessment was inde-
pendently performed by a neuroradiologist (RF), accord-
ing to RANO criteria [11]. These data were subsequently
compared to Macdonald criteria evaluation [18]. Table 1
summarizes the response assessment criteria as adapted from
Wen et al. [11].
Pseudoprogression was defined as a 25% increase in
tumor size or any new lesion followed by stabilization (stable
disease) or response (partial or complete), with no therapy
modification, for at least 6 months after completing the
concomitant phase of the RT/TMZ [19]. According to RANO
criteria, progression within <12 weeks after completion
of chemoradiotherapy was only defined if there was new
enhancement outside of the radiation field (beyond the high-
dose region or 80% isodose line) or if there was unequiv-
ocal evidence of viable tumor on histopathologic sampling.
So, given the difficulty of differentiating true progression
from pseudoprogression, clinical decline alone as well as an
increase of contrast enhancement within the radiotherapy
field was not considered sufficient for definition of progres-
sive disease within the first 12 weeks after completion of
concurrent chemoradiotherapy [11].
Demographic data are collected and summarized in
Table 2.
Temozolomide was administered at a dose of 75mg
perm2 concurrent with daily radiotherapy and followed by
150–200mg per m2 for 5 days every 28 days. Radiation was
delivered in 2Gy/fr, for a total of 60Gy in 30 fractions.
Patients were first categorized as having early progression if
there was progression at the first follow-up scan 1 to 3months
after chemoradiotherapy andno early progression if therewas
stable or responsive disease. Patients with early progression
were further subdivided in pseudoprogression and true
progression according to further radiological progression.
2.1. Statistics. The primary endpoint was the frequency of
pseudoprogression and its effect on prognosis.The secondary
endpoints were overall survival and progression-free survival
calculated from the date of surgery. Kaplan-Meier product-
limit analysis was conducted and 95% confidence intervals
were calculated. Log-rank test was used to detect statisti-
cally significant differences in survival distributions. Data of
patients who have not progressed or died were right censored
in our analysis. Multivariate survival analysis using a for-
ward stepwise Cox regression model was used to determine
independent predictors of survival. Borderline significant
variables (𝑃 ≤ 0.1) were included in the final model. SPSS
software version 19.0 was used for the statistical analysis.
3. Results
At the first MRI scan performed 1 month after concurrent
RT/TMZ, early progression was recorded in 42 patients
(60%), while 28 patients were considered to have nonpro-
gressive disease (nPD), according to Macdonald criteria.
Thirty-four patients (81%) met the Macdonald criteria for
progression due to a 25% increase in tumor size, 4 patients
(9.5%) due to new lesions and 4 patients (9.5%) due to clinical
deterioration. Out of the 42 patients with early progres-
sion there were 32 patients (76%) with further progression
(tPD) and 10 (24%) patients with stable or reduced le-
sion—pseudoprogression (psPD) (Figure 1). Regarding nPD
patients, 26 patients (93%) had stable disease and 2 patients
(7%) showed partial response during subsequent follow-up.
When considering RANO criteria for progression within
the first 12 weeks after completion of concurrent chemora-
diotherapy, there were only 15 patients (21%) who met the
criteria for progressive disease, while 55 patients (79%) were
considered to have nonprogressive disease, either stable dis-
ease (27 patients), partial response (1 patient) or an increase
of contrast enhancement within the radiotherapy field (27
patients), also considered stable disease. Out of the 15
early progressive patients, there were 14 patients with new
enhancement areas outside of the radiation field and 1 patient
with evidence of viable tumor on histopathologic sampling.
Subsequently, 13 patients (87%) showed further progression
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Table 1: Criteria for response assessment in high-grade gliomas.
Response Criteria
Macdonald criteria RANO criteria
Complete response
All: complete disappearance of all enhancing measurable
and nonmeasurable diseases sustained for at least 4 weeks,
no new lesions, no corticosteroids, and being stable or
improved clinically.
All: T1 gadolinium enhancing disease, none; T2/FLAIR,
stable or decreasing; new lesion, none; corticosteroids,
none; clinical status: stable or improving.
Partial response
All: ≥50% decrease in sum of products of perpendicular
diameters of all measurable enhancing lesions sustained
for at least 4 weeks, no new lesions, stable or reduced
corticosteroid dose, and being stable or improved
clinically.
All: T1 gadolinium enhancing disease, ≥50% decrease;
T2/FLAIR, stable or decreasing; new lesion, none;
corticosteroids, stable or decreasing; clinical status: stable
or improving.
Stable disease All: being not qualified for complete response, partialresponse, or progression; being stable clinically.
All: T1 gadolinium enhancing disease: <50% decrease but
<25% increase; T2/FLAIR: stable or decreasing; new
lesion: none; corticosteroids: stable or decreasing; clinical
status: stable or improving.
Progression
Any: ≥25% increase in sum of the products of
perpendicular diameters of enhancing lesions, any new
lesion, or clinical deterioration.
Any: T1 gadolinium enhancing disease: ≥25% increase;
T2/FLAIR: increasing; new lesion: none; corticosteroids:
not applicable; clinical status: deteriorating.
RANO: Response Assessment in Neuro-Oncology; FLAIR: fluid-attenuated inversion recovery.
Table 2: Demographic data of population.
Characteristics Patients
Number %
Age, years
Median 62
Range 34–78
Gender
Male 46 66
Female 24 34
ECOG
0 18 25.7
1-2 43 61.4
3 9 12.9
Surgery
Biopsy 14 20
Partial resection 32 46
Total resection 24 34
Adjuvant TMZ cycles
Mean 5
Range 0–20
Corticotherapy
Stable 43 61
Increased 11 16
Reduced 16 23
(tPD) and 2 patients (13%) showed stable disease representing
pseudoprogression (psPD).
In fact, RANO criteria were specifically structured to
make overcalling of early progression in the first 3months dif-
ficult, so, as expected, progressive disease <12 weeks as
assessed by RANO criteria revealed a lower value.
After progressive disease in the first MRI 1 month after
concurrent RT/TMZ, we observed dissociated responses
between T2/FLAIR and T1-contrast-enhanced imaging in 3
patients in whom stabilization or decreasing enhancement
was accompanied by an increase in T2/FLAIR signal without
any modification in therapy (Figure 2). Subsequent imaging
confirmed progression.
Regarding corticosteroid therapy in psPD group, 5 pa-
tients showed stable dose, 4 had decreasing doses, and only
1 had transient dose increment.
Functional status remained stable in patients with pseu-
doprogression according to the ECOG performance status.
3.1. Survival Analysis. Thewhole cohort median survival and
median progression-free survival were 15 months [95% CI
(13.64, 16.36)] and 10 months [95% CI (8.02, 11.98)], respec-
tively. The only independent predictors of survival were the
number of TMZ cycles and the type of surgery (Table 3).
Interestingly, multivariate analysis showed that the number
of TMZ cycles was a strong predictor for survival regardless
of the ECOG status.
Survival analysis for subgroups of progression according
toMacdonald criteria revealed amedian overall survival of 12
months [95% CI (8.7, 15.3)] for the group of true progressive
disease and 21 months [CI 95% (14.5, 27.5)] for the group
of nonprogressive disease. Pseudoprogression group had a
median overall survival of 24 months [CI 95% (11.6, 36.4)],
not statistically different from the nonprogressive group (𝑃 =
0.456). According to RANO criteria, true progressive disease
group had amedian overall survival of 9months [95%CI (3.7,
14.3)] and nonprogressive disease group had amedian overall
survival of 16 months [95% CI (13.8, 18.2)]. Pseudoprogres-
sion group was limited to 2 patients with an estimate median
overall survival of 13 months, not statistically different from
the nonprogressive group (𝑃 = 0.639) (Figure 3). Median
progression-free survival for true progressive disease, pseu-
doprogression, and nonprogressive disease was 6 months,
16 months, and 12 months, respectively (Macdonald criteria
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Figure 1: T1-contrast-enhanced and FLAIR magnetic resonance imaging (MRI) documenting pseudoprogression. Compared with pre-
RT/TMZMRI, the 1-month post-RT/TMZ showed increasing areas of contrast enhancement suggestive of tumoral progression. The patient
remained clinically stable with stable dose of corticotherapy. Adjuvant TMZ treatment cycles were maintained and serial MRI at 4, 7, 10, and
15 months showed a consistent reduction in the size and the contrast of the lesion as well as in FLAIR signal.
Pre RT/TMZ 1M post RT/TMZ 3M post RT/TMZ 5M post RT/TMZ
FLAIR
T1WI post Gd
Figure 2: T1-contrast-enhancedmagnetic resonance imaging (MRI) documenting pseudoprogression according toMacdonald criteria show-
ing a significant increase in cingulate gyrus enhancing lesion at 1 month after RT/TMZ with subsequent stabilization (stable corticosteroid
dose and functional status). FLAIR sequence shows increased signal extending to contralateral hemisphere anticipating true progressive
disease.
applied) and 6months, 7 months, and 11 months, respectively
(RANO criteria applied) (Figure 4).
Comparing the survival distributions, patients with pseu-
doprogression showed a statistically significant improved
overall survival over patients with true progressive disease
(𝑃 = 0.01) and an increased time to progression (𝑃 <
0.001), according to Macdonald response assessment. Sur-
vival curves of psPD and nPD closely overlap showing no sta-
tistical difference (𝑃 = 0.456). Regarding RANO assessment
group, the low rate of pseudoprogression (2/15 patients, 13%)
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Table 3: Analysis of independent predictors of survival in the cohort of glioblastoma patients submitted to chemoradiotherapy.
Variable Univariate analysis Multivariate analysis
HR 95% CI 𝑃 value HR 95% CI 𝑃 value
Age
≥60 versus <60 years 1.26 0.75–2.10 0.389 — — —
Gender
M versus F 0.98 0.57–1.69 0.943 — — —
Type of surgery
Biopsy versus total or subtotal resection 3.47 1.83–6.58 <0.001 2.60 1.35–4.99 0.004
Number of surgeries
1 versus >1 0.97 0.54–1.75 0.921 — — —
Corticosteroids
Increasing versus stable or decreasing 1.04 0.54–2.02 0.903 — — —
ECOG
0–2 versus >2 0.34 0.17–0.72 0.005 ns
Number of TMZ cycles
≥6 versus <6 0.16 0.09–0.29 <0.001 0.18 0.10–0.32 <0.001
CI: confidence interval; HR: hazard ratio; M: male; F: female; TMZ: temozolomide; ECOG: Eastern Cooperative Oncology Group; ns: nonsignificant. Results
indicated in bold are significant. Multivariate analysis used Cox proportional hazards model with a forward stepwise regression procedure.
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Figure 3: Kaplan-Meier analysis of overall survival curves according to different progression groups: true-progressive disease (tPD), blue;
Pseudoprogression (psPD), green; Nonprogressive disease (nPD), yellow; and different response assessment criteria: (a), Macdonald; (b),
RANO.
did not provide enough statistical power to allow significant
statistical conclusions in this particular group.
4. Discussion
Pseudoprogression is characteristically found within 2 to 3
months after treatment but can occur at 6 months and may
progress over time into treatment-related necrosis [17, 31].
The issue of contrast enhancement areas starts even before
adjuvant therapy administration. Farace et al. studied early
MRI changes in the period between surgery and adjuvant
therapy by diffusion-weighted imaging and MR perfusion,
concluding that areas of new contrast enhancement of
resected GBM are frequently observed in this period (17/37,
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Figure 4: Kaplan-Meier analysis of progression-free survival curves according to different progression groups: true-progressive disease (tPD),
blue; pseudoprogression (psPD), green; nonprogressive disease (nPD), yellow; and different response assessment criteria: (a) Macdonald and
(b) RANO.
46%) and that most of them are suggestive of tumor pro-
gression (14/17; 82%) [32]. Distinguishing treatment induced
imaging changes from true progressive disease can be espe-
cially difficult in the period immediately following comple-
tion of radiotherapy [8]. Standard MR imaging techniques
do not allow a clear distinction between recurrent tumour
and radiation-induced lesion [33].TheMRI characteristics of
pseudoprogression have been described as an asymptomatic
increase in contrast enhancement [34]. Enhancement of brain
tumors primarily reflects a disturbed blood-brain barrier,
and all the processes that decrease or increase this abnormal
permeability will affect the area of enhancement, regardless
of the size and activity of the tumor [31]. According to the
literature, pseudoprogression occurs in 12 to 64% of patients.
Table 4, as adapted from Kruser et al., summarizes the data
[5, 8, 10, 12–14, 17, 19–29].
Topkan et al. evaluated pathological confirmed incidence
of pseudoprogression in a cohort of 63 patients. Pseudopro-
gression was identified in 12 out of 28 patients with early
progressive disease (42.8%), representing an overall pseudo-
progression rate of 19% [30]. The wide range of variation in
retrospective cohorts might be explained by different criteria
used to establish the response and, also, by considering
different time periods. We only considered early progression
in the first 3months, and by this we could have lost some pro-
gressive patients. Our rates of 13 to 24% of pseudoprogression
are in line with the literature. We retrospectively reviewed
RANO criteria and compared them to Macdonald criteria
since the latter do not take into account progressive nonen-
hancing disease, disregarding enlarging areas of nonenhanc-
ing tumor as evidence of tumor progression. Recently, a
study comparing several response assessment criteria in
recurrent GBM concluded a strong concordance between
methods but noticed that criteria integrating FLAIR hyper-
intensity tended to reduce response rates and progression-
free survival comparedwith criteria considering only contrast
enhancement [35]. The decreased rate of pseudoprogression
in our data after RANO evaluation reflects the improvement
in response assessment. In fact, as discussed elsewhere,
tumor progression as determined by both contrast-enhanced
T1 and T2 sequences is more frequently diagnosed than
when considering only contrast-enhanced T1 sequences [36].
Currently, changes in T2/FLAIR are not based on objective
or volumetric measures due to technical limitations and
insufficient standardization but should include mass effect
and infiltration of the cortical ribbon or location outside of
the radiation field [11].
The abnormal enhancement seen in pseudoprogression
may be the result of treatment-related cellular hypoxia, which
results in expression of hypoxia-regulated molecules from
tumor and surrounding cells with the subsequent increased
vascular permeability/increased tumor enhancement [7].
Pseudoprogression likely involves early changes to the vas-
cular endothelium and the blood-brain-barrier [5]. It may be
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Table 4: Rates of pseudoprogression reported in the literature in patients treated with radiotherapy and temozolomide.
Author Year Number ofpatients Response criteria
Period of early-response
assessment (months)
Number
with ePD
psPD
(% of ePD)
Overall rate of
psPD
Chamberlain
et al. [20] 2007 51 Not specified 6 26 7/15 (47%) 7/40 (18%)
Brandes et al. [13] 2008 103 Macdonald 1 50 32/50 (64%) 32/103 (31%)
Taal et al. [19] 2008 68 Macdonald 1 31 15/31 (48%) 15/68 (22%)
Chaskis et al. [21] 2009 54 Gd-MRI + clinical 6 25 3/12 (12%) 3/54 (6%)
Clarke and Chang
[22] 2009 85 Macdonald 0.5–1 35 10/27 (37%) 10/77 (13%)
Fabi et al. [23] 2009 12 Macdonald 2 4 2/4 (50%) 2/12 (17%)
Peca et al. [24] 2009 50 Gd-MRI + MRSpectroscopy 6 15 4/15 (27%) 4/50 (8%)
Roldan et al. [8] 2009 43 Macdonald 1–1.5 25 10/20 (50%) 10/38 (26%)
Gerstner et al. [25] 2009 45 Macdonald 0.5–1 24 13/24 (54%) 13/45 (29%)
Sanghera et al. [5] 2010 104 RECIST 2 27 7/22 (32%) 7/99 (7%)
Tsien et al. [10] 2010 27 Macdonald 3 14 6/14 (43%) 6/27 (22%)
Yaman et al. [26] 2010 67 Gd-MRI + T2/FLAIR 6 17 4/17 (24%) 4/67 (6%)
Gunjur et al. [27] 2011 68 Macdonald 1 41 14/41 (34%) 14/68 (21%)
Kang et al. [12] 2011 35 Macdonald 1 18 8/18 (44%) 8/35 (23%)
Kong et al. [17] 2011 90 Macdonald + rCBV 2 59 26/59 (44%) 26/90 (29%)
Young et al. [28] 2011 321 Macdonald 0.5–1 205 30/93 (32%) Not specified
Park et al. [29] 2011 48 Macdonald 1 25 11/25 (44%) 11/48 (23%)
Topkan et al. [30] 2012 63 Macdonald 6 28 12/28 (43%) 12/63 (19%)
Pouleau et al. [14] 2012 63 Gd-MRI + edema 2 33 7/33 (21%) 7/63 (11%)
Present study 2013 70 RANOMacdonald 3
15
42
2/15 (13%)
10/42 (24%)
2/70 (3%)
10/70 (14%)
ePD: early progressive disease; tPD: true progressive disease; psPD: pseudoprogression; Gd-MRI: gadolinium enhanced-MRI.
considered as a pathological continuum between acute post-
RT reaction and treatment-related necrosis. More recently,
Kruser et al. in their comprehensive review highlight the
dichotomybetweenpseudoprogression—as a clinical diagno-
sis in the absence of intervention, and RT necrosis which can
only be defined upon reoperation or biopsy [37].Mechanisms
behind these events are not fully understood but are probably
related tomicrovessels changes. Post-RT brain injury induces
a focal tissue reaction with inflammatory component and
increased capillary permeability, causing fluid transudation
into the interstitial space and brain oedema. Transient alter-
ations in the blood-brain barrier may be responsible for
new or increased contrast enhancement, falsely suggesting
tumour progression, with low perfusion values [33].
There is also evidence that treatment-related necrosis
occurs more frequently and earlier after temozolomide
chemotherapy than after radiotherapy alone [31]. The MRI
characteristics of pseudoprogression are similar to those of
radiation necrosis, and conventional sequences are unable to
distinguish between the two [28]. Corpus callosum involve-
ment, subependymal spread, or multiple enhancing lesions
are more consistent with progressive disease than pseudo-
progression but are not able to reliably discriminate between
both responses [28, 38]. Additionally, nonenhanced tumor is
usually not considered in response evaluation as shown in the
several retrospective studies. This represents a strong limita-
tion in response assessment. Some advancedMRI techniques
have shown promising results of distinguishing posttreat-
ment necrosis from tumor progression and pseudoprogres-
sion, including MR spectroscopy (higher Cho/Cr and Cho/
NAA ratios), MR perfusion imaging, and diffusion-weighted
MRI, namely, relative cerebral blood volume (rCBV) as
an imaging biomarker for increased neoangiogenesis and
apparent diffusion coefficient (ADC) value as an imaging bio-
marker of increased cellular density [10, 17, 38–41].
Our data are in agreement with the literature as we
have noticed an increase in overall survival and in time to
progression in patients with pseudoprogression compared to
patients with true progression as assessed by classical cri-
teria. On the other hand, our results show no differences
between the pseudoprogression patients and the patients
with nonprogressive disease in contrast to some authors
who report survival benefit in pseudoprogression patients
[13] although the small number of patients enrolled in our
study may preclude conclusions on the significance of this
finding. RANO criteria assessment provided a very low rate
of pseudoprogression patients due to the stringent nature
of these criteria, especially within the first 12 weeks after
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chemoradiotherapy, as shown by the low rate of progressive
disease during this period. This prevented definitive conclu-
sions regarding the prognostic value of RANO criteria. Some
authors reported that while incidence of pseudoprogression
strongly depends on the applied criteria, the impact on
survival remains the same, regardless of the stringency of the
criteria [42]. The prognostic accuracy of different response
assessment criteria is, however, yet to be proven in stud-
ies of greater magnitude. Nonetheless, the importance of
making overcall of early progression difficult with RANO
criteria cannot be overemphasized. Failure to exclude patients
with pseudoprogression from recurrent gliomas trials with
resulting falsely high responses rates and PFS demands the
implementation of these strict criteria [11].
The data presented address the issue of the variability
of pseudoprogression phenomenon when evaluated with
conventional MRI. Novel reliable biochemical and imaging
biomarkers are emerging and prospectively designed, and
validated investigation is needed to conclude their clinical
impact.
5. Conclusions
Pseudoprogression is a phenomenon that appears after
chemoradiation therapy for high-grade gliomas, and its
pathophysiology is not fully understood. Rates vary widely
and are dependent on themethodof evaluation.TheMacdon-
ald criteria do not take into account all variables implicated
in pseudoprogression and are being replaced. In this cohort
of GBM patients, the frequency of pseudoprogression varied
between 13% and 24%, being over-diagnosed by the older
Macdonald criteria, which emphasizes the importance of
RANO criteria and new radiological biomarkers for correct
response evaluation. The accurate diagnosis of pseudopro-
gression is essential to avoid modifications of effective ther-
apies or unnecessary treatments for GBM patients. More
studies are needed to conclude the prognostic relevance of the
different response assessment criteria.
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